A few years ago, if you wanted a number that summarized how well your body was aging, you had your chronological age and not much else. Now there's a growing menu of tests that promise something different: a "biological age" that supposedly reflects how your body is actually doing, independent of your birthday. Epigenetic clocks built on DNA methylation patterns, telomere length panels, blood-biomarker composites, even algorithms trained on gait and grip strength. All of them return the same kind of answer: a single number, usually framed as younger or older than you'd expect.
The idea underneath this is sound. Chronological age is a weak proxy for the thing people actually care about, which is how much functional capacity and disease risk a person is carrying. Two 55-year-olds can have very different cardiovascular systems, different inflammatory profiles, different odds of showing up in a hospital in the next ten years. A number that captures more of that variation than "years since birth" would be genuinely useful, for patients and for the systems trying to allocate preventive care sensibly.
What the science actually supports right now
The strongest evidence sits with epigenetic clocks trained and validated against real outcomes: mortality, cardiovascular events, cancer incidence, frailty. Several of these have shown a statistically meaningful association with those outcomes in large cohort studies, on top of what chronological age and standard risk factors already predict. That's a real, published finding, not marketing.
What it is not is a validated individual diagnostic. Most of that evidence comes from population-level studies: cohorts of thousands of people, followed for years, with the biological-age measure showing a statistical association with group-level outcomes. That's different from a test that can tell one specific person, with clinical precision, how many years they have left or what disease is coming. Population-level association and individual-level prediction are not the same claim, and a lot of the marketing around these tests quietly slides from one to the other.
Where the evidence runs out
Three gaps show up consistently when you look past the press release. First, reproducibility: run the same person's sample through two different labs or two different clock algorithms, and the "biological age" answer can shift by years, because the field hasn't converged on one validated method. Second, actionability: even where a test flags accelerated aging, the evidence base for which specific intervention reverses that specific signal, in that specific person, is thin. Third, regulation: most of these tests are sold direct-to-consumer as wellness products, not as FDA-cleared diagnostics, which means they haven't been held to the evidence bar that a clinical test would need to clear.
None of that means the field is worthless. It means the number on the report is a data point, not a verdict.
How I'd think about it
If a biological age test tells you something that changes what you'd actually do, differently, from evidence-based advice you'd act on anyway, it's earned its cost, whether or not the underlying number is precise. If it's mainly producing anxiety, or a false sense of certainty in either direction, it's the same trap as the wearables readiness score I've written about before: a proprietary number standing in for real evidence.
The systems point matters here too. As biological age testing moves from novelty to a real category, healthcare organizations that want to offer it responsibly need to be honest with patients about which claims are validated and which are still provisional, build the intervention pathway before the test, not after, and resist the pressure to let a compelling-sounding number substitute for what a real risk assessment requires.
The bar I'd apply
Population-level evidence is real. Individual-level precision is not there yet. That gap is exactly where good medicine and good marketing tend to diverge, and it's worth watching closely as more of these tests move from research cohorts into consumer products.